Cisplatin: mode of cytotoxic action and molecular basis of resistance
The DOI matches its Crossref record; 156 of the 156 references it cites were found in a registry or an index.
Abstract
Cisplatin is one of the most potent antitumor agents known, displaying clinical activity against a wide variety of solid tumors. Its cytotoxic mode of action is mediated by its interaction with DNA to form DNA adducts, primarily intrastrand crosslink adducts, which activate several signal transduction pathways, including those involving ATR, p53, p73, and MAPK, and culminate in the activation of apoptosis. DNA damage-mediated apoptotic signals, however, can be attenuated, and the resistance that ensues is a major limitation of cisplatin-based chemotherapy. The mechanisms responsible for cisplatin resistance are several, and contribute to the multifactorial nature of the problem. Resistance mechanisms that limit the extent of DNA damage include reduced drug uptake, increased drug inactivation, and increased DNA adduct repair. Origins of these pharmacologic-based mechanisms, however, are at the molecular level. Mechanisms that inhibit propagation of the DNA damage signal to the apoptotic machinery include loss of damage recognition, overexpression of HER-2/neu, activation of the PI3-K/Akt (also known as PI3-K/PKB) pathway, loss of p53 function, overexpression of antiapoptotic bcl-2, and interference in caspase activation. The molecular signature defining the resistant phenotype varies between tumors, and the number of resistance mechanisms activated in response to selection pressures dictates the overall extent of cisplatin resistance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ATM kinase seems to be activated primarily in response to the induction of double-strand breaks whereas ATR is critical for cellular checkpoint responses to stalled replication forks and to many types of DNA damage, such as those induced by UV light and cisplatin (16,17).”
In the citing paper
“Clinical use of cisplatin is complicated by the dose-limiting side effects as well as rapid development of drug resistance [5].”
Citations
Cites
1 retracted
BRCA1 required for transcription-coupled repair of oxidative DNA damage
Gowen, L. C., Avrutskaya, A. V., Latour, A. M., Koller, B. H., & Leadon, S. A. (1998) · Science · doi:10.1126/science.281.5379.1009 · Cited by 496
RetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018 · cited 1×
“A major factor affecting the loss of apoptotic function is p53 gene mutation (see Figure 6), which is observed in about a half of all cancers (Hollstein et al., 1991; Soussi, 2000).”
BackgroundStudies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Bcl-2 functions in an antioxidant pathway to prevent apoptosis
Hockenbery, D. M., Oltvai, Z. N., Yin, X.-M., Milliman, C. L., & Korsmeyer, S. J. (1993) · Cell · doi:10.1016/0092-8674(93)80066-n · Cited by 3,419
Hartwell, L. H., & Kastan, M. B. (1994) · Science · doi:10.1126/science.7997877 · Cited by 2,535
Regulation of Cell Death Protease Caspase-9 by Phosphorylation
Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E., Frisch, S., & Reed, J. C. (1998) · Science · doi:10.1126/science.282.5392.1318 · Cited by 2,481
Mitogen-activated protein kinase pathways
Robinson, M. J., & Cobb, M. H. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80061-0 · Cited by 2,474
DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100 · cited 2×
“Intracellular factors that may inhibit such an activation of p53 include overexpression of the negative feedback regulator Mdm2 and downregulation of the moderator of Mdm2, p14ARF (Fritsche et al., 1993; Shieh et al., 1997; Lakin and Jackson, 1999; Meek, 1999; Deng et al., 2002).”
BackgroundA family of drug transporters: the multidrug resistance-associated proteins
Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751 · cited 1×
“…resistance-associated (MRP) gene family, composed of at least seven members (MRP1–7), has been a major target of investigations, primarily as several of these ABC membrane proteins have been found in tumor cells and associated with cellular efflux of a variety of drugs (Borst et al., 2000).”
Background
Research works printed but not linked: 5
- Eischen CM, Kottke TJ, Martins LM, Basi GS, Tung JS, Earnshaw WC, Leibson PJ and Kaufmann SH. (1997). Blood, 90, 935–943. · doi:10.1182/blood.v90.3.935.935_935_943 · Paper page
- Eisenhauer E, Swerton K, Sturgeon J, Fine S, O'Reilly S and Canetta R . (1990). Carboplatin: Current Perspectives and Future Directions. Bunn P, Canetta R, Ozols R and Rozencweig M (eds). WB Saunders Company: Philadelphia, PA, pp. 133–140.
- He G and Siddik ZH . (2001). Proc. Am. Assoc. Cancer Res., 42, 901.
- Holford J, Rogers P and Kelland LR . (1998). Int. J. Cancer, 77, 94–100. · doi:10.1002/(sici)1097-0215(19980703)77:1<94::aid-ijc15>3.0.co;2-9
- Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, Jones LA, El Naggar A, Minguillon C, Schonborn I, Reich O, Kreienberg R, Lichtenegger W and Press MF . (2001). Clin. Cancer Res., 7, 2984–2997.
Cited by
Items 101–200 of 1,004
Copper in tumors and the use of copper-based compounds in cancer treatment
da Silva, D. A., De Luca, A., Squitti, R., Rongioletti, M., Rossi, L., Machado, C. M. L., & Cerchiaro, G. (2022) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2021.111634 · Cited by 241
Wu, M., Wang, Y., Yang, D., Gong, Y., Rao, F., Liu, R., Danna, Y., Li, J., Fan, J., Chen, J., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.02.012 · Cited by 240
“DDP is a potent apoptotic chemotherapy drug that is effective against many tumours [28].”
BackgroundSimons, A. L., Ahmad, I. M., Mattson, D. M., Dornfeld, K. J., & Spitz, D. R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3717 · Cited by 238
Liu, D., Yang, Y., Liu, Q., & Wang, J. (2011) · Medical Oncology · doi:10.1007/s12032-009-9397-3 · Cited by 233
Targeting the ATR-CHK1 Axis in Cancer Therapy
Rundle, S., Bradbury, A., Drew, Y., & Curtin, N. (2017) · Cancers · doi:10.3390/cancers9050041 · Cited by 231
Activation and involvement of p53 in cisplatin-induced nephrotoxicity
Wei, Q., Dong, G., Yang, T., Megyesi, J., Price, P. M., & Dong, Z. (2007) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00230.2007 · Cited by 232
Zhang, Q., Deng, T., Zhang, H., Zuo, D., Zhu, Q., Bai, M., Liu, R., Ning, T., Zhang, L., Yu, Z., et al. (2022) · Advanced Science · doi:10.1002/advs.202203357 · Cited by 229
Drug transporters of platinum-based anticancer agents and their clinical significance
Burger, H., Loos, W. J., Eechoute, K., Verweij, J., Mathijssen, R. H. J., & Wiemer, E. A. C. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2010.12.002 · Cited by 230
Li, L., He, D., Guo, Q., Zhang, Z., Ru, D., Wang, L., Gong, K., Liu, F., Duan, Y., & Li, H. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01264-5 · Cited by 206
Cisplatin-Based Chemotherapy of Human Cancers.
Brown, A. M., Kumar, S., & Tchounwou, P. B. (2019) · PubMed · Cited by 318
Colon cancer: Cancer stem cells markers, drug resistance and treatment
Kozovska, Z., Gabrisova, V., & Kucerova, L. (2014) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2014.10.019 · Cited by 228
The Mechanism of Drug Nephrotoxicity and the Methods for Preventing Kidney Damage
Kwiatkowska, E., Domański, L., Dziedziejko, V., Kajdy, A., Stefańska, K., & Kwiatkowski, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116109 · Cited by 222
“Glutathione is the main cellular antioxidant, and its consumption by cisplatin metabolites causes ROS accumulation and oxidative stress [46].”
BackgroundInhibition of Cell Growth and VEGF Expression in Ovarian Cancer Cells by Flavonoids
Luo, H., Jiang, B.-H., King, S. M., & Chen, Y. C. (2008) · Nutrition and Cancer · doi:10.1080/01635580802100851 · Cited by 224
Li, M., Balch, C., Montgomery, J. S., Jeong, M., Chung, J. H., Yan, P., Huang, T. H., Kim, S., & Nephew, K. P. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-34 · Cited by 225
Dysregulation of the basal RNA polymerase transcription apparatus in cancer
Bywater, M. J., Pearson, R. B., McArthur, G. A., & Hannan, R. D. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3496 · Cited by 222
Monofunctional and Higher-Valent Platinum Anticancer Agents
Johnstone, T. C., Wilson, J. J., & Lippard, S. J. (2013) · Inorganic Chemistry · doi:10.1021/ic400538c · Cited by 223
Mechanisms of Chemotherapeutic Drug Resistance in Cancer Therapy—A Quick Review
Liu, F.-S. (2009) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/s1028-4559(09)60296-5 · Cited by 220
Dickey, D. T., Wu, Y. J., Muldoon, L. L., & Neuwelt, E. A. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.087601 · Cited by 219
The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer
Madhusudan, S., & Middleton, M. R. (2005) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2005.09.006 · Cited by 218
Patra, B., Peng, C.-C., Liao, W.-H., Lee, C.-H., & Tung, Y.-C. (2016) · Scientific Reports · doi:10.1038/srep21061 · Cited by 215
Ahmad, S. (2010) · Chemistry & Biodiversity · doi:10.1002/cbdv.200800340 · Cited by 215
PARP inhibitor combination therapy
Dréan, A., Lord, C. J., & Ashworth, A. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.10.010 · Cited by 212
Arafa, E.-S. A., Zhu, Q., Shah, Z. I., Wani, G., Barakat, B. M., Racoma, I., El-Mahdy, M. A., & Wani, A. A. (2011) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2010.10.007 · Cited by 210
“Multiple factors contribute to development of drug resistance of cancer cells, including reduction of intracellular drug accumulation, increase in DNA damage repair, constitutive activation of PI3K/Akt signaling, activation of the Ras and MAPK pathways, dysfunction of the tumor suppressor gene p53 [43].”
BackgroundLiu, Y.-P., Yang, C.-J., Huang, M.-S., Yeh, C.-T., Wu, A. T. H., Lee, Y.-C., Lai, T.-C., Lee, C.-H., Hsiao, Y.-W., Lu, J., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1733 · Cited by 210
Regulation of PUMA-α by p53 in cisplatin-induced renal cell apoptosis
Jiang, M., Wei, Q., Wang, J., Du, Q., Yu, J., Zhang, L., & Dong, Z. (2006) · Oncogene · doi:10.1038/sj.onc.1209440 · Cited by 209
Ling, X., Chen, X., Riddell, I. A., Tao, W., Wang, J., Hollett, G., Lippard, S. J., Farokhzad, O. C., Shi, J., & Wu, J. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b01924 · Cited by 209
Targeting Glucose Metabolism to Overcome Resistance to Anticancer Chemotherapy in Breast Cancer
Varghese, E., Samuel, S. M., Líšková, A., Samec, M., Kubatka, P., & Büsselberg, D. (2020) · Cancers · doi:10.3390/cancers12082252 · Cited by 208
“Additionally, an attenuation of Ras and MAPK pathway also mediates cisplatin resistance [178].”
BackgroundHierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death
Tajeddine, N., Galluzzi, L., Kepp, O., Hangen, E., Morselli, E., Senovilla, L., Araujo, N., Pinna, G., Larochette, N., Zamzami, N., et al. (2008) · Oncogene · doi:10.1038/onc.2008.63 · Cited by 208
“…confirmed pro-apoptotic protein known to participate in CDDPelicited lethal signaling, including breast cancer 1 (BRCA1) (Bartz et al., 2006), p53 (Siddik, 2003), apoptotic peptidase-activating factor-1 (Zermati et al., 2007), Bak and Bax (alone and in combination) (Wang et al., 2001; Kepp et…”
BackgroundFOXM1 Confers Acquired Cisplatin Resistance in Breast Cancer Cells
Kwok, J. M.-M., Peck, B., Monteiro, L. J., Schwenen, H. D. C., Millour, J., Coombes, R. C., Myatt, S. S., & Lam, E. W.-F. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0432 · Cited by 207
Aminoglycoside- and Cisplatin-Induced Ototoxicity: Mechanisms and Otoprotective Strategies
Kros, C. J., & Steyger, P. S. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a033548 · Cited by 207
“Aquated cisplatin binds to nuclear DNA forming adducts that prevent transcription and replication, ultimately resulting in apoptosis, the basis of its cytotoxic antitumor activity, particularly in proliferating cancer cells that are poor at repairing DNA damage (Siddik 2003).”
BackgroundActivation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance
Brozovic, A., & Osmak, M. (2007) · Cancer Letters · doi:10.1016/j.canlet.2006.10.007 · Cited by 204
Teiten, M.-H., Eifes, S., Dicato, M., & Diederich, M. (2010) · Toxins · doi:10.3390/toxins2010128 · Cited by 204
A platinum‐based covalent viability reagent for single‐cell mass cytometry
Fienberg, H. G., Simonds, E. F., Fantl, W. J., Nolan, G. P., & Bodenmiller, B. (2012) · Cytometry Part A · doi:10.1002/cyto.a.22067 · Cited by 202
Hayakawa, J., Mittal, S., Wang, Y., Korkmaz, K. S., Adamson, E., English, C., Omichi, M., McClelland, M., & Mercola, D. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.10.024 · Cited by 204
Wan, X., Beaudoin, J. J., Vinod, N., Min, Y., Makita, N., Bludau, H., Jordan, R., Wang, A., Sokolsky, M., & Kabanov, A. V. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2018.10.032 · Cited by 201
Signalling cell cycle arrest and cell death through the MMR System
O'Brien, V., & Brown, R. (2006) · Carcinogenesis · doi:10.1093/carcin/bgi298 · Cited by 201
Role of Oxidative Stress in Drug-Induced Kidney Injury
Hosohata, K. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111826 · Cited by 199
“First, cisplatin is actuated into a highly reactive form, which can rapidly react with thiol-containing molecules including glutathione (GSH), a well-recognized cellular antioxidant [57,58].”
BackgroundAngeles-Boza, A. M., Bradley, P. M., Fu, P. K.-L., Wicke, S. E., Bacsa, J., Dunbar, K. R., & Turro, C. (2004) · Inorganic Chemistry · doi:10.1021/ic049091h · Cited by 199
Biologic Basis for Combining Drugs With Radiation
WILSON, G., BENTZEN, S., & HARARI, P. (2006) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2005.08.001 · Cited by 198
Huang, X., Okafuji, M., Traganos, F., Luther, E., Holden, E., & Darzynkiewicz, Z. (2004) · Cytometry Part A · doi:10.1002/cyto.a.20018 · Cited by 197
“Single-strand DNA breaks, however, appear during the nucleotide excision repair of the CP-induced lesions (31,32).”
BackgroundHIF Activation Protects From Acute Kidney Injury
Weidemann, A., Bernhardt, W. M., Klanke, B., Daniel, C., Buchholz, B., Ca[Combining Circumflex Accent]mpean, V., Amann, K., Warnecke, C., Wiesener, M. S., Eckardt, K.-U., et al. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007040419 · Cited by 196
Ai, Z., Lu, Y., Qiu, S., & Fan, Z. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.01.009 · Cited by 195
“The cytotoxic mode of action of cisplatin is well established and is mediated by interaction of cisplatin with DNA to form DNA adducts, primarily intrastrand crosslink adducts [36].”
BackgroundInfluentialCisplatin induces PKB/Akt activation and p38MAPK phosphorylation of the EGF receptor
Winograd-Katz, S. E., & Levitzki, A. (2006) · Oncogene · doi:10.1038/sj.onc.1209737 · Cited by 195
Nakashima-Kamimura, N., Mori, T., Ohsawa, I., Asoh, S., & Ohta, S. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0924-2 · Cited by 194
Liu, L.-Z., Zhou, X.-D., Qian, G., Shi, X., Fang, J., & Jiang, B.-H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4261 · Cited by 189
Zhang, W., Shen, J., Su, H., Mu, G., Sun, J.-H., Tan, C.-P., Liang, X.-J., Ji, L.-N., & Mao, Z.-W. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b03881 · Cited by 187
Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics
Wijdeven, R. H., Pang, B., Assaraf, Y. G., & Neefjes, J. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.07.001 · Cited by 187
A Novel, Evolutionarily Conserved Protein Phosphatase Complex Involved in Cisplatin Sensitivity
Gingras, A.-C., Caballero, M., Zarske, M., Sanchez, A., Hazbun, T. R., Fields, S., Sonenberg, N., Hafen, E., Raught, B., & Aebersold, R. (2005) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m500231-mcp200 · Cited by 186
Nojima, K., Hochegger, H., Saberi, A., Fukushima, T., Kikuchi, K., Yoshimura, M., Orelli, B. J., Bishop, D. K., Hirano, S., Ohzeki, M., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1214 · Cited by 185
Targeting the RNA Polymerase I Transcription for Cancer Therapy Comes of Age
Ferreira, R., Schneekloth, J. S., Panov, K. I., Hannan, K. M., & Hannan, R. D. (2020) · Cells · doi:10.3390/cells9020266 · Cited by 183
“These adducts are detected by DNA repair proteins that become irreversibly bound to the DNA leading to cell death by mechanisms such as cell cycle arrest or inhibition of protein synthesis [60].”
BackgroundFOXM1 (Forkhead box M1) in Tumorigenesis
(2013) · Advances in Cancer Research · doi:10.1016/b978-0-12-407190-2.00016-2 · Cited by 184
APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
Mohell, N., Alfredsson, J., Fransson, Å., Uustalu, M., Byström, S., Gullbo, J., Hallberg, A., Bykov, V. J. N., Björklund, U., & Wiman, K. G. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.143 · Cited by 183
“Many studies have shown that glutathione, which has an important role in maintaining the cellular oxidative balance, is involved in resistance to DNA-damaging drugs including platinum compounds and classical alkylating agents.(7,15,21,23,24,25) Intracellular glutathione exists in a balance between the reduced form (GS…”
BackgroundInfluentialWu, Y. J., Muldoon, L. L., & Neuwelt, E. A. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.075119 · Cited by 183
Morgan, S., Lopes, F., Gourley, C., Anderson, R. A., & Spears, N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070117 · Cited by 180
Multi-action Pt(IV) anticancer agents; do we understand how they work?
Gibson, D. (2019) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2018.11.008 · Cited by 180
The Transcription Factor FOXM1 (Forkhead box M1)
(2013) · Advances in Cancer Research · doi:10.1016/b978-0-12-407173-5.00004-2 · Cited by 176
Curcumin: A potentially powerful tool to reverse cisplatin-induced toxicity
Rezaee, R., Momtazi, A. A., Monemi, A., & Sahebkar, A. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2016.12.037 · Cited by 175
Mechanism of Cell Adaptation: When and How Do Cancer Cells Develop Chemoresistance?
Fodale, V., Pierobon, M., Liotta, L., & Petricoin, E. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e318212dd3d · Cited by 175
Schäfer, S., Ott, I., Gust, R., & Sheldrick, W. S. (2007) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.200700206 · Cited by 175
Role of p53 in cisplatin-induced tubular cell apoptosis: dependence on p53 transcriptional activity
Jiang, M., Yi, X., Hsu, S., Wang, C.-Y., & Dong, Z. (2004) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00262.2004 · Cited by 175
Chen, L., Wang, L., Tsang, N., Ojcius, D. M., Chen, C., OuYang, C., Hsueh, C., Liang, Y., Chang, K., Chen, C., et al. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201201569 · Cited by 173
PARP inhibitors: enhancing efficacy through rational combinations
Bhamidipati, D., Haro-Silerio, J. I., Yap, T. A., & Ngoi, N. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02326-7 · Cited by 169
“Combinations of PARPis with platinum chemotherapy lead to cross-linking of DNA strands, which prevents DNA replication and transcription, leading to cell cycle arrest, and eventual apoptosis [125].”
BackgroundQuercetin reduces cisplatin nephrotoxicity in rats without compromising its anti-tumour activity
Sanchez-Gonzalez, P. D., Lopez-Hernandez, F. J., Perez-Barriocanal, F., Morales, A. I., & Lopez-Novoa, J. M. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr195 · Cited by 173
Wang, K., Zhu, C., He, Y., Zhang, Z., Zhou, W., Muhammad, N., Guo, Y., Wang, X., & Guo, Z. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201900387 · Cited by 171
MicroRNA-mediated drug resistance in breast cancer
Kutanzi, K. R., Yurchenko, O. V., Beland, F. A., Checkhun, V. F., & Pogribny, I. P. (2011) · Clinical Epigenetics · doi:10.1007/s13148-011-0040-8 · Cited by 170
“Indeed, resistance to cisplatin has been correlated with MRP2-mediated efflux of cisplatin–GSH complexes (Konig et al. 1999; Siddik 2002, 2003).”
BackgroundKim, D.-H., Choi, H.-I., Park, J. S., Kim, C. S., Bae, E. H., Ma, S. K., & Kim, S. W. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102382 · Cited by 167
“Cisplatin reacts rapidly with thiol-containing antioxidant molecules such as glutathione and is converted to a highly reactive form, and when glutathione is depleted, intracellular oxidative stress increases [30].”
BackgroundSarin, N., Engel, F., Kalayda, G. V., Mannewitz, M., Cinatl, J., Rothweiler, F., Michaelis, M., Saafan, H., Ritter, C. A., Jaehde, U., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0181081 · Cited by 168
“Cisplatin cytotoxicity has been suggested to be predominantly mediated by nuclear DNA binding, mainly via intrastrand DNA crosslinks leading to cell cycle arrest and subsequent apoptosis [5].”
BackgroundMechanism of Apoptosis Induced by Curcumin in Colorectal Cancer
Ismail, N. I., Othman, I., Abas, F., H. Lajis, N., & Naidu, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102454 · Cited by 166
“Gastrointestinal ulcerations, kidney damage [10], hearing loss and balance [7] [11–13], tumor resistance [14,15], hypertension, fatigue, hand-foot skin reaction, diarrhea [16], and nausea are the list of adverse side effects associated with the chemotherapy treatment.”
BackgroundHearn, J. M., Romero-Canelón, I., Qamar, B., Liu, Z., Hands-Portman, I., & Sadler, P. J. (2013) · ACS Chemical Biology · doi:10.1021/cb400070a · Cited by 166
Cho, J.-M., Manandhar, S., Lee, H.-R., Park, H.-M., & Kwak, M.-K. (2008) · Cancer Letters · doi:10.1016/j.canlet.2007.10.022 · Cited by 166
Wu, X., Gu, J., Wu, T.-T., Swisher, S. G., Liao, Z., Correa, A. M., Liu, J., Etzel, C. J., Amos, C. I., Huang, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6640 · Cited by 166
Awuah, S. G., Zheng, Y.-R., Bruno, P. M., Hemann, M. T., & Lippard, S. J. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b10182 · Cited by 164
Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer
Wagner, A. H., Devarakonda, S., Skidmore, Z. L., Krysiak, K., Ramu, A., Trani, L., Kunisaki, J., Masood, A., Waqar, S. N., Spies, N. C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06162-9 · Cited by 163
Usanova, S., Piée-Staffa, A., Sied, U., Thomale, J., Schneider, A., Kaina, B., & Köberle, B. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-248 · Cited by 162
Huang, R. S., Duan, S., Shukla, S. J., Kistner, E. O., Clark, T. A., Chen, T. X., Schweitzer, A. C., Blume, J. E., & Dolan, M. E. (2007) · The American Journal of Human Genetics · doi:10.1086/519850 · Cited by 163
Current status of excision repair cross complementing-group 1 (ERCC1) in cancer
Gossage, L., & Madhusudan, S. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.07.001 · Cited by 162
Peng, K., Liang, B.-B., Liu, W., & Mao, Z.-W. (2021) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.214210 · Cited by 162
TRAIL Agonists on Clinical Trials for Cancer Therapy: The Promises and the Challenges
Bellail, A., Qi, L., Mulligan, P., Chhabra, V., & Hao, C. (2009) · Reviews on Recent Clinical Trials · doi:10.2174/157488709787047530 · Cited by 161
Role of copper transporters in the uptake and efflux of platinum containing drugs
Safaei, R. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.07.046 · Cited by 160
The epigenetics of ovarian cancer drug resistance and resensitization
Balch, C., Huang, T. H.-M., Brown, R., & Nephew, K. P. (2004) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.05.025 · Cited by 160
Ferreira, J. A., Peixoto, A., Neves, M., Gaiteiro, C., Reis, C. A., Assaraf, Y. G., & Santos, L. L. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2015.11.003 · Cited by 159
Wood, L. M., & Paterson, Y. (2014) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2014.00051 · Cited by 157
Evaluating the molecule-based prediction of clinical drug responses in cancer
Ding, Z., Zu, S., & Gu, J. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw344 · Cited by 158
“As we know, cisplatin binds to DNA, induces DNA damages and kills cells via inducing apoptosis (Siddik, 2003).”
BackgroundSamimi, G., Katano, K., Holzer, A. K., Safaei, R., & Howell, S. B. (2004) · Molecular Pharmacology · doi:10.1124/mol.66.1.25 · Cited by 158
The Role of ClpP Protease in Bacterial Pathogenesis and Human Diseases
Bhandari, V., Wong, K. S., Zhou, J. L., Mabanglo, M. F., Batey, R. A., & Houry, W. A. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00124 · Cited by 173
Li, X., Wang, G., Zhao, J., Ding, H., Cunningham, C., Chen, F., Flynn, D. C., Reed, E., & Li, Q. Q. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5027-1 · Cited by 155
Mechanisms of platinum drug resistance
Ohmichi, M., Hayakawa, J., Tasaka, K., Kurachi, H., & Murata, Y. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.01.002 · Cited by 159
Rebillard, A., Tekpli, X., Meurette, O., Sergent, O., LeMoigne-Muller, G., Vernhet, L., Gorria, M., Chevanne, M., Christmann, M., Kaina, B., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0353 · Cited by 156
Metal complexes as potential modulators of inflammatory and autoimmune responses
Leung, C., Lin, S., Zhong, H., & Ma, D. (2015) · Chemical Science · doi:10.1039/c4sc03094j · Cited by 171
Li, J., Gui, Y., Ren, J., Liu, X., Feng, Y., Zeng, Z., He, W., Yang, J., & Dai, C. (2016) · Scientific Reports · doi:10.1038/srep23975 · Cited by 152
Regulation and Pathological Role of p53 in Cisplatin Nephrotoxicity
Jiang, M., & Dong, Z. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.139162 · Cited by 162
Therapeutic Targeting of ATP7B in Ovarian Carcinoma
Mangala, L. S., Zuzel, V., Schmandt, R., Leshane, E. S., Halder, J. B., Armaiz-Pena, G. N., Spannuth, W. A., Tanaka, T., Shahzad, M. M. K., Lin, Y. G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2306 · Cited by 154
Self-citationChemotherapy Resistance in Lung Cancer
Kim, E. S. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-24223-1_10 · Cited by 160
Corte‐Rodríguez, M., García, R. Á.-F., Blanco, E., Bettmer, J., & Montes‐Bayón, M. (2017) · Analytical Chemistry · doi:10.1021/acs.analchem.7b02746 · Cited by 154
Lu, Y., Pan, Q., Gao, W., Pu, Y., & He, B. (2022) · Journal of Materials Chemistry B · doi:10.1039/d2tb01150f · Cited by 154
Hsu, D. S.-S., Lan, H.-Y., Huang, C.-H., Tai, S.-K., Chang, S.-Y., Tsai, T.-L., Chang, C.-C., Tzeng, C.-H., Wu, K.-J., Kao, J.-Y., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0593 · Cited by 152
The molecular and cellular basis of copper dysregulation and its relationship with human pathologies
Maung, M. T., Carlson, A., Olea‐Flores, M., Elkhadragy, L., Schachtschneider, K. M., Navarro‐Tito, N., & Padilla‐Benavides, T. (2021) · The FASEB Journal · doi:10.1096/fj.202100273rr · Cited by 174
Dzagnidze, A., Katsarava, Z., Makhalova, J., Liedert, B., Yoon, M.-S., Kaube, H., Limmroth, V., & Thomale, J. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.0523-07.2007 · Cited by 152
Salim, K. Y., Maleki Vareki, S., Danter, W. R., San-Marina, S., & Koropatnick, J. (2106) · Oncotarget · doi:10.18632/oncotarget.9133 · Cited by 148
Turkson, J., Zhang, S., Mora, L. B., Burns, A., Sebti, S., & Jove, R. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m502694200 · Cited by 151
Metadata
- Authors
- Siddik, Z. H.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Siddik, Zahid H
- ORCID
- Siddik, Zahid H
- Venue
- Oncogene
- Published
- 2003-10-20
- Volume
- 22
- Issue
- 47
- Pages
- 7265-7279
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2164277862
- Cited by
- 3,335
- References
- 154
- Citations by year
- 2026: 67 · 2025: 94 · 2024: 127 · 2023: 161 · 2022: 195 · 2021: 216 · 2020: 203 · 2019: 181 · 2018: 184 · 2017: 185 · 2016: 215 · 2015: 193 · 2014: 205 · 2013: 175 · 2012: 165
- FWCI
- 7.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ca077332-03)
- National Cancer Institute (CA-77332, R01CA082361, CA 82361)
- Topics
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- cisplatin, cisplatin resistance, DNA adducts, DNA cross-linking, apoptosis, ATR signaling, p53, p73, MAPK signaling, DNA damage response, drug uptake, drug inactivation, DNA repair, HER2/neu, PI3K/Akt signaling, Bcl-2, caspase activation, signal transduction
- MeSH terms
- Cisplatin, DNA Damage, DNA Repair, Humans, Tumor Suppressor Protein p53, Apoptosis, Drug Resistance, Neoplasm, MAP Kinase Signaling System
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.